Hello, Fool! | Login | Signup | My Fool
Oct 13, 2008 1:29 PM ET | Feedback | Site Changes | Help
A global pharmaceutical company, which develops, produces and markets generic drugs covering all major treatment categories.
View All Commentary (TEVA)
Recs
mdriver78 (< 20) Submitted: 10/31/06 11:35 PM : Start Price: $32.65 TEVA Score: 54.09
Co announces, in conjunction with the release of the Sanofi-Aventis (SNY) financial results, that global in-market sales of Copaxone in Q306 grew by 15% as compared to Q305 and reached a record of $354 mln. U.S. sales in Q306 increased 10% over the Q305 to $226 mln. Outside the U.S., mainly in Europe, Copaxone grew 26% over Q305, reaching sales of $128 mln.
Report this Post Replies: 0 | Reply
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK